1. Introduction {#s0005}
===============

Paclitaxel is an extremely effective chemotherapeutic agent for the treatment of breast, ovarian, and lung cancer ([@bb0225]). However, paclitaxel-induced peripheral neuropathy (PIPN), a major dose-limiting toxicity, occurs in 59% to 87% of patients who receive this drug ([@bb0155]; [@bb0350]). Paclitaxel is an anti-tubulin drug that causes microtubule stabilization. In the peripheral nervous system, administration of paclitaxel results in distal axonal degeneration, secondary demyelination, and nerve fiber loss.([@bb0115]; [@bb0345]).

A growing body of evidence has implicated neuroinflammation in the development of PIPN ([@bb0265]; [@bb0400]). While most chemotherapy (CTX) drugs do not cross the blood-brain-barrier, they readily penetrate the blood-nerve-barrier and bind to and accumulate in dorsal root ganglia (DRG) and peripheral axons.([@bb0115]; [@bb0310]) In addition to its direct neurotoxic effects, CTX can induce neuroinflammation through activation of immune and immune-like glial cells. In fact, a growing body of preclinical evidence suggests that immune cells (e.g., macrophages, lymphocytes) and glial cells (e.g., Schwann cells) in the peripheral nervous system (PNS) and astrocytes and microglia in the central nervous system (CNS) play an important role in the induction and maintenance of neuropathic pain.([@bb0215]; [@bb0420]) This activation of the immune system results in the release of inflammatory mediators, within the DRG and dorsal horn, ([@bb0215]) that enhances neuronal excitability and results in pain hypersensitivity in peripheral neurons ([@bb0265]).

Not all patients develop neurotoxicity, which suggests that molecular factors may play a role in the development of PIPN. In fact, in our recent report, using RNA-seq data from breast cancer patients who did (*n* = 25) and did not (n = 25) develop PIPN,([@bb0205]) we identified nine perturbed pathways that were associated with various aspects of mitochondrial dysfunction including oxidative stress, iron homeostasis, mitochondrial fission, apoptosis, and autophagy. In this paper, we extend these findings and describe differentially perturbed pathways, as well as whole transcriptome profiles of differential gene expression (DGE), associated with neuroinflammation, in the same sample of breast cancer survivors with (*n* = 25) and without (*N* = 25) chronic PIPN.

2. Materials and methods {#s0010}
========================

2.1. Study design {#s0015}
-----------------

In this study, we used two different approaches to evaluate whole transcriptome data for patterns of DGE in biological pathways associated with neuroinflammation and PIPN ([Fig. 1](#f0005){ref-type="fig"} ). The first approach utilized pathway impact analysis (PIA), where well-defined signaling pathways are evaluated for perturbations using the significance and magnitude of gene-gene interactions from DGE tests. For the second approach (i.e., Expression Profile Analysis (EPA)), we compared our whole transcriptome pattern of DGE between breast cancer survivors with and without CIPN to a database of publicly available and well annotated gene expression experiments to identify other systems and studies with similar patterns. For this analysis, we used demographic, clinical, and gene expression data from our previous study ([@bb0205]).Fig. 1An overview of the analytic approach used to evaluate for neuroinflammation related pathways and gene expression experiments associated with paclitaxel-induced peripheral neuropathy (PIPN). Differential gene expression (DGE) in peripheral blood was found between breast cancer survivors with (P) and without (N) paclitaxel-induced peripheral neuropathy and evaluated for (1) perturbed neuroinflammation related signaling pathways using pathway impact analysis and (2) experiments from the gene expression omnibus (GEO) with similar whole-transcriptome profiles of differential gene expression related to neuroinflammation and PIPN using expression profile analysis. Taken together, our results suggest that perturbations in pro- and anti-inflammatory pathways associated with neuroinflammation are found in cancer survivors with PIPN.Fig. 1

2.2. Acquisition and processing of gene expression data {#s0020}
-------------------------------------------------------

The methods for the gene expression analysis are described in detail elsewhere.([@bb0205]) Gene expression of total RNA isolated from peripheral blood was assayed using RNA-seq. Gene expression was summarized as counts per gene and used as input for the PIA and EPA analyses.

2.3. Pathway impact analysis {#s0025}
----------------------------

Differential gene expression was quantified using general linear models ([@bb0205]). These DGE analyses were adjusted for demographic (i.e., age, employment status) and clinical (i.e., Alcohol Use Disorders Identification Test (AUDIT)([@bb0020]) score, body mass index (BMI), Karnofsky Performance Score (KPS)([@bb0165]; [@bb0170]; [@bb0355]) score) characteristics that differed between the PIPN groups, as well as for technical variability (e.g., potential batch effects). The DGE results were summarized as the log fold change and *p*-value for each gene. Then, PIA was used to evaluate for perturbations in well-defined signaling pathways. PIA includes potentially important biological factors (e.g., gene-gene interactions, flow signals in a pathway, pathway topologies), the magnitude (i.e., log fold-change), and *p*-values from the differential expression (DE) analysis (reviewed in ([@bb0285])). The PIA included the results of the DE analysis for all genes (i.e., cutoff free) to determine probability of pathway perturbations (pPERT) using Pathway Express.([@bb0090]).

A total of 208 signaling pathways were defined using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database.([@bb0005]) Sequence loci data were annotated with Entrez gene IDs. The gene symbols were annotated using the HUGO Gene Nomenclature Committee resource database.([@bb0120]) We assessed for significance of the PIA using a strict false discovery rate (FDR) of \<1 under the Benjamini-Hochberg (BH) procedure.([@bb0015]; [@bb0135]) Finally, we evaluated these results specifically for pathways related to neuroinflammation.

2.4. Expression profile analysis {#s0030}
--------------------------------

To evaluate the whole transcriptome pattern of DGE in relationship to neuroinflammation and PIPN, we compared these findings with independent and well annotated publicly available data sets of gene expression. We utilized ProfileChaser([@bb0100]) to develop a transcriptome wide 'profile' of the DGE pattern between the PIPN and no PIPN groups and compared this profile to all of the NCBI Gene Expression Omnibus (GEO) curated GEO DataSets (GDS) available. These GDS include gene expression data from a wide variety of tissues, species, and study designs. Each study is annotated with a number of characteristics termed as 'factors' (e.g., sample ID, age, cell line, treatment group).

ProfileChaser generates reference profiles from all of the pairwise comparisons of all of the factors defined in a GDS. Then, it compares the query dataset to identify similar reference profiles. In this way, ProfileChaser identifies experiments with similar biological conditions to the query experiment. By performing this evaluation of all available GDS and their annotated factors, we limit any bias from a priori filtering. Gene level summaries of RNA abundance were annotated with ENTREZ ID and estimated as the log transformed reads per mean thousand (i.e., log~2~(RPMK+1)). We assessed for significance of the EPA using a strict FDR of 5% under the BH procedure.([@bb0015]; [@bb0135]) Using our previous method,([@bb0195]) we evaluated the significant findings for interpretability based on the experimental design of the reference profile.

3. Results {#s0035}
==========

3.1. Differences in demographic, clinical, pain, sensation, and balance characteristics {#s0040}
---------------------------------------------------------------------------------------

As previously reported ([@bb0205]), survivors with PIPN were significantly older (*p* = .006) and were more likely to be unemployed (*p* = .022) In terms of clinical characteristics, survivors with PIPN had: a lower AUDIT score (*p* = .012), a higher body mass index (BMI; *p* = .017), and a lower KPS score (*p* \< .001). Of note, no between group differences were found in the total cumulative dose of paclitaxel received or in the percentage of patients who had a dose reduction or delay due to PIPN (see [Supplementary Table 1](#ec0005){ref-type="supplementary-material"}, [Supplementary Table 2](#ec0010){ref-type="supplementary-material"}).

[Supplementary Table 3](#ec0015){ref-type="supplementary-material"} summarizes the self-reported pain characteristics of the survivors with PIPN. Worst pain severity was reported as 6.3 (±2.1) out of ten and the duration of PIPN was 3.8 (±3.9) years.

Supplementary Table 3 summarizes the self-reported pain characteristics of the survivors with PIPN. Worst pain severity was reported as 6.3 (±2.1) out of ten and the duration of PIPN was 3.8 (±3.9) years.

Survivors with PIPN had a higher number of lower extremity sites with loss of light touch, cold, and pain sensations (all, *p* \< .05). Vibration thresholds were significantly higher in the PIPN group (*p* = .009, [Supplementary Table 4](#ec0020){ref-type="supplementary-material"}).

Survivors with PIPN were more likely to report trouble with balance (*p* \< .001) as well as higher severity and distress (both p \< .05) scores associated with balance problems. In addition, these survivors reported worse Timed Get Up and Go (*p* = .001) and worse Fullerton Advanced Balance (*p* = .004) scores ([Supplementary Table 4](#ec0020){ref-type="supplementary-material"}).

3.2. PIA of the whole transcriptome {#s0045}
-----------------------------------

Successful annotation with ENTREZ IDs was performed for 11,174 unique genes. Fold changes and *p*-values from the DE analysis for these genes were included in the pathway perturbation analysis of the 208 KEGG signaling pathways. PIA identified 53 KEGG signaling pathways that were significantly perturbed between the PIPN groups after correction for multiple hypothesis testing at a conservative FDR of 1% (adjusted perturbation p-value \<.01). Of these, 8 KEGG signaling pathways were related to neuroinflammation ([Table 1](#t0005){ref-type="table"} ).Table 1Significantly perturbed neuroinflammatory related KEGG pathways between breast cancer survivors with and without paclitaxel-induced peripheral neuropathy.Table 1Pathway IDPathway nameTotal perturbationAdjusted pPert[a](#tf0005){ref-type="table-fn"}hsa04060Cytokine-cytokine receptor interaction6.370.004hsa04064NF-kappa B signaling pathway4.500.005hsa04727GABAergic synapse4.630.007hsa04920Adipocytokine signaling pathway9.130.008hsa04657IL-17 signaling pathway3.150.010hsa04621NOD-like receptor signaling pathway11.320.004hsa04152AMPK signaling pathway15.140.004hsa04350TGF-beta signaling pathway10.300.010[^1][^2]

3.3. EPA of the whole transcriptome {#s0050}
-----------------------------------

Whole transcriptome profiles were evaluated for similarity in DGE between our sample of survivors with and without PIPN and the 280 profiles across 84 unique GDS that were identified using EPA (Supplementary File 1). After an evaluation of the study designs of these 280 profiles, 27 profiles from 15 unique GDS and 13 published studies were identified to be associated with neuroinflammation and PIPN. These findings were organized into six categories based on their similar biological characteristics ([Table 2](#t0010){ref-type="table"} ).Table 2Whole-transcriptome gene expression GEO datasets with similar profiles to breast cancer survivors with CIPN vs. without CIPN.Table 2GEO IDReference[a](#tf0010){ref-type="table-fn"}OrganismPrimary comparisonPrimary factorScoreq-valueTissuePre-clinical models of neuropathic painGDS2159*M.m.*Sham SCI vs. naïveProtocol0.4280.025SCGDS2159*M.m.*28d vs 0 h post SCITime0.3830.037SCGDS2159*M.m.*7d vs 0 h post SCITime0.3790.037SCGDS2159*M.m.*Moderate SCI vs. naïveProtocol0.3740.037SCGDS2439*R.n.*28d vs 50d after L5 SNLTime0.3520.046DRGGDS25912,666,113*R.n.*3d vs 2d after SCI at T9Time0.3520.056SCGDS33912,666,113*R.n.*3d vs 2d after SCI at T9Time0.3480.047SC  Response to infectionGDS102815,655,079*H.s.*SARS vs controlDisease state0.3990.031PBMCGDS149915,897,992*H.s.*Control vs. HIV-1, drug regimen not indicatedProtocol0.4010.031PBMCGDS149915,897,992*H.s.*HIV-1 seronegative vs HIV-1 seropositiveDisease state0.4000.033PBMCGDS149915,897,992*H.s.*Control vs. HIV-1, drug naïveProtocol0.3530.045PBMCGDS197130,638,864*H.s.*Complicated malaria vs healthyDisease state0.5690.007PWBGDS197130,638,864*H.s.*Uncomplicated malaria vs healthyDisease state0.4530.020PWBGDS236216,988,231*H.s.*Presymptomatic vs experimentally acquired malariaUninfected0.4690.017PBMC  Neurological conditionGDS131116,043,692*H. s.*HD symptomatic vs normalDisease state0.4630.018PWBGDS131116,043,692*H. s.*HD presymptomatic vs. normalDisease state0.4640.025PWB  Exercise-induced effectsGDS231016,990,507*H.s.*After exhaustive vs. before moderate exerciseTime0.6800.003WBCGDS231016,990,507*H.s.*After exhaustive vs. before exhaustive exerciseTime0.6540.003WBCGDS231016,990,507*H.s.*After exhaustive vs. after moderate exerciseTime0.5570.008WBCGDS231016,990,507*H.s.*After moderate vs. before moderate exerciseTime0.5170.011WBCGDS2417*H.s.*Post-exercise vs. pre-exerciseProtocol0.3830.036WBCGDS96215,194,674*H.s.*60 min after vs before exerciseTime0.5010.012PBMC  Inflammatory bowel diseaseGDS161516,436,634*H.s.*Crohn\'s disease vs normalDisease state0.4870.015PBMCGDS161516,436,634*H.s.*Ulcerative colitis vs. normalDisease state0.4190.027PBMC  HematopoiesisGDS232118,268,278*H.s.*G-CSF vs pegylated G-CSFAgent0.4120.028CD34(+) cellsGDS2959*H.s.*G-CSF vs untreatedAgent0.5360.010PWBGDS781*H.s.*G-CSF treated vs untreatedAgent0.4290.025PBMC[^3][^4]

4. Discussion {#s0055}
=============

4.1. Perturbed neuroinflammation-related pathways associated with PIPN {#s0060}
----------------------------------------------------------------------

This study is the first to provide molecular evidence that a number of neuroinflammatory mechanisms identified in preclinical models of neuropathic pain and/or PIPN([@bb0110]; [@bb0255]) are perturbed in cancer survivors with PIPN. As noted in a review on the role of cytokines in chemotherapy-induced peripheral neuropathy (CIPN),([@bb0400]) pro-inflammatory cytokines and chemokines play a critical role in the development and maintenance of painful peripheral neuropathy. Consistent with our findings of a differential perturbation in the cytokine-cytokine receptor interaction pathway, several lines of pre-clinical evidence suggest that the administration of paclitaxel is associated with the activation of immune and immune-like cells in both the PNS and CNS. For example, following the administration of intravenous paclitaxel in rats, the number of activated macrophages in the DRG, peripheral nerves, and Schwann cells increased and was associated with allodynia and hyperalgesia.([@bb0315]) Macrophage infiltration results in the production and release of a number of cytokines (e.g., tumor necrosis factor alpha (TNF-α), interleukin 6 (IL6)) and chemokines. In addition, Schwann cells release TNF-α, IL6, prostaglandin E2 (PGE2), and adenosine triphosphate (ATP).([@bb0300]) All of these molecules contribute to neuroinflammation.([@bb0370]; [@bb0385]).

Additional evidence from preclinical models of peripheral neuropathy supports our finding of perturbations in the nuclear factor (NF)-κβ signaling pathway. For example, building on the observation that NF-κβ immunoreactive neurons are increased on the ipsilateral side of a partial sciatic nerve injury,([@bb0250]) the effects of NF-κβ in PIPN were evaluated in a rodent model.([@bb0160]) In this study, paclitaxel increased the protein levels of spinal phosphorylated NF-κβ and an NF-κβ inhibitor attenuated mechanical hyperalgesia. The authors concluded that the activation of NF-κβ mediates paclitaxel-induced hyperalgesia. In another preclinical study,([@bb0125]) the intraperitoneal administration of paclitaxel induced the activation of NF-κβ; the upregulation of TNF-α, IL1β, and IL6; and astrocyte activation in the spinal cord.

Another perturbed pathway in our study was the IL17 signaling pathway. The IL17 family is a subset of cytokines that play crucial roles in both acute and chronic inflammatory responses.([@bb0140]) IL17 is produced by CD4^+^ T cells and appears to play a role in inflammatory([@bb0245]) and neuropathic([@bb0080]; [@bb0185]) pain. In the most recent preclinical study,([@bb0375]) expression of IL17 in the spinal cord was evaluated following spinal nerve ligation. During the maintenance phase of neuropathic pain, mRNA expression levels of IL17, IL1β, and IL6 were significantly increased in the dorsal horn of the spinal cord of animals with the nerve injury. The authors concluded that IL17 may contribute to neuropathic pain by promoting the proliferation of astrocytes and the secretion of pro-inflammatory cytokines. While no studies were found on the role of IL17 in CIPN, astrocytes appear to play a role in the development of this chronic pain condition.([@bb0335]; [@bb0340]).

In terms of perturbations in the adipocytokine signaling pathway, leptin is an important regulator of energy intake and metabolic rate. In addition, leptin influences the normal functioning of the immune system through the stimulation of cytokine production and chemotaxis. In addition, leptin expression can be regulated by cytokines.([@bb0045]) While no studies were found on associations between leptin and CIPN, in a rat model of chronic constriction injury, administration of a leptin antagonist prevented the development of injury-induced mechanical allodynia and thermal hyperalgesia.([@bb0240]) In a mouse model of partial sciatic nerve ligation,([@bb0260]) leptin production was induced in the adipocytes that were present in the epineurium of the injured nerve and leptin was necessary for tactile allodynia associated with the ligation. In addition, leptin enhanced the production of cyclo‑oxygenase (COX)-2, inducible nitric oxide synthase (iNOS), and matrix metalloprotease-9 from macrophages that suggests that adipokines activate macrophages that contribute to the development of neuropathic pain. However, in another preclinical study, leptin exhibited protective effects in a model of sciatic nerve injury.([@bb0105]).

The various members of the nucleotide-binding and oligomerization domain (NOD)-like receptor signaling pathway play pivotal roles in the recognition of intracellular ligands. Of particular interest is the growing body of evidence that suggests that one member of this pathway (i.e., NOD-like receptor protein 3 (NLRP3)) is involved in various types of neuropathic pain.([@bb0175]; [@bb0235]; [@bb0305]; [@bb0320]; [@bb0390]; [@bb0410]) Of note, in a recent preclinical study of PIPN in rats,([@bb0150]) paclitaxel increased the expression of and activated fragments of caspase-1 and IL1β which suggests activation of the NLRP3 inflammasome. The expression of NLRP3 was located in CD68 macrophages that infiltrated the L4--5 DRG and sciatic nerve. The authors concluded that their findings suggest that the administration of paclitaxel induced mitochondrial damage and reactive oxygen species production that resulted in the activation of the NLRP3 inflammasome in peripheral nerves and contributes to PIPN ([@bb0150]).

While no preclinical studies were identified that implicate the transforming growth factor (TGF)-β signaling pathway in the development of PIPN, this pathway includes a number of structurally related cytokines that have a wide spectrum of cellular functions. Within the nervous system, TGF-β1 controls the proliferation of neurons and regulates neuronal survival.([@bb0220]) In astroglia, TGF-β1 exerts anti-inflammatory and immunosuppressive effects.([@bb0030]) In preclinical studies, TGF-β1 prevented the development of neuropathic pain associated with traumatic nerve injury and reversed previously established neuropathic pain.([@bb0055]; [@bb0050]; [@bb0095]).

Gamma amino butyric acid (GABA) is the most abundant inhibitory neurotransmitter within the CNS. In various models of neuropathic pain, decreases in GABA receptor-mediated inhibitory synaptic transmission in dorsal horn neurons occurs following nerve injury.([@bb0130]; [@bb0415]) In addition, in a mouse model of PIPN,([@bb0035]) the intraspinal transplantation of cortical precursors of GABAergic interneurons from the embryonic medial ganglionic eminence reversed both the mechanical allodynia and heat hyperalgesia associated with the administration of paclitaxel.

As noted in a recent review,([@bb0010]) the adenosine monophosphate-activated protein kinase (AMPK) signaling pathway is a novel target for the alleviation of neuropathic pain. AMPK activators inhibit signaling pathways that are known to promote changes peripheral nociceptors that result in chronic pain. In the only study that evaluated the role of AMPK in CIPN,([@bb0270]) the co-administration of platinum with metformin, a drug that activates AMPK, prevented the increased latency associated with detection of an adhesive patch, as well as the decrease in the density of intra-dermal nerve fibers following the administration of CTX in a mouse model.

4.2. Whole-transcriptome profiles of DGE {#s0065}
----------------------------------------

Using EPA, we identified similar profiles in experimental systems of inflammatory responses, exercise-induced effects, and pre-clinical models of pain (see [Table 2](#t0010){ref-type="table"}). In terms of inflammatory responses, similar profiles of DGE were found between our survivors with and without PIPN and patients with SARS,([@bb0330]) HIV-1,([@bb0290]) and malaria([@bb0025]; [@bb0295]) who were compared to healthy or pre-symptomatic individuals. As noted above, neuroinflammation is thought to play a major role in the development and maintenance of PIPN (Makker, Duffy, 2017, [@bb0400]). The similarities between our chronic PIPN profile and these pathogen-mediated inflammatory profiles suggests that systemic inflammatory processes may play a role in the development and maintenance of PIPN.

In terms of the findings related to exercise-mediated effects, limited evidence exists that exercise benefits some patients with various types of neuropathic pain,([@bb0085]) including CIPN.([@bb0190]) In our study, compared to survivors without PIPN (87.5%), only 60.0% of the survivors with PIPN reported that they exercised on a regular basis (*p* = .051). In the EPA, the DGE profiles in the blood from healthy volunteers that was taken before and after increasing levels of exercise ([@bb0040]; [@bb0070]) were similar to the profile in our survivors with and without PIPN. Additional research is warranted on this association because in our two previous analyses of CIPN([@bb0280]) and PIPN([@bb0200]) in larger samples of survivors who were heterogenous in terms of their cancer diagnoses and/or CTX regimens, no associations were found between the use of regular exercise and the occurrence of neuropathic pain.

Of note, seven profiles from two pre-clinical models of neuropathic pain (i.e., spinal cord injury (SCI)([@bb0365]) and L5 spinal nerve ligation (SNL)([@bb0060]; [@bb0180])) share a similar whole transcriptome profile of DGE with our cohort. It is important to note that while our survivors\' DGE profile was derived using blood samples, the preclinical findings came from a different species (i.e., rodents) and different tissues (i.e., spinal cord, DRG). Gene expression differences across tissues are mainly driven by a small number of genes,([@bb0275]) suggesting that gene expression changes in one tissue may provide insights into gene expression patterns in another tissue. Changes in gene expression in whole blood have been used as a marker for neuronal injury.([@bb0380]) In addition, gene expression patterns in blood, hippocampus, and pre-frontal cortex show broad levels of co-expression.([@bb0405]) Given the recent interest in evaluating for concordance and discordance in the expression of genes that represent known biomarkers and therapies across tissues([@bb0210]), the controversy about whether changes in GE in peripheral blood reflects changes within the PNS and CNS ([@bb0065]; [@bb0360]; [@bb0145]), and our findings of similarities between human whole blood and pre-clinical models of neuropathic pain in neuronal tissue (i.e., rat DRG (GDS2439) and mouse SC (GDS2159)), future research should evaluate for genes that are similar and unique to these tissue types in relation to PIPN. Another point worth noting is that in some of the preclinical studies that were identified using EPA, differences in GE were evaluated days to months after the nerve injury. This evaluation time frame is consistent with a more chronic pain phenotype and perhaps is more relevant to our cohort of survivors who had PIPN for 3.8 (±3.9) years. The EPA analysis did not evaluate for any specific preclinical or human studies of CIPN or PIPN.

4.3. Conclusions {#s0070}
----------------

Taken together, these findings suggest that in addition to perturbed pathways associated with mitochondrial dysfunction ([@bb0205]), perturbations in pro- and anti-inflammatory pathways associated with neuroinflammation are found in cancer survivors with PIPN. Furthermore, whole transcriptome profiles of DGE patterns in preclinical and clinical studies provide additional support for our findings.

4.4. Limitations {#s0075}
----------------

Several limitations need to be considered. While our sample size was relatively small, we had an extremely well characterized sample of breast cancer survivors with and without PIPN. Of note, no differences were found in the total cumulative dose of paclitaxel that these survivors received. Although not significantly different between groups in this study, exercise regularity may contribute to differences in differential gene expression between breast cancer survivors with and without PIPN. Given that an evaluation of differences in gene expression from DRG neurons cannot be done in living individuals, like others,([@bb0230]; [@bb0395]) we evaluated for differences in RNA expression using peripheral blood. Some limitations of using whole blood to evaluate for patterns of expression in other tissues include: blood shows the largest number of uniquely expressed genes ([@bb0275]); blood has the smallest number of expressed transcripts across tissues;([@bb0075]) and baseline blood does not share similar whole-transcriptome pattern with DRG, as well as other CNS or PNS tissue.([@bb0325]).

4.5. Future research {#s0080}
--------------------

This study is the first to provide molecular evidence that neuroinflammatory mechanisms identified in preclinical models of various types of neuropathic pain including CIPN (Makker, Duffy, 2017; [@bb0400]), are found in peripheral blood leukocytes of cancer survivors with persistent PIPN. Despite the limitations of the analyses of RNA from blood, we did observe profiles of DGE and perturbations in these processes, which suggest persistent damage and/or changes in the PNS. Given that these survivors had PIPN for approximately four years, our findings suggest that chronic neuroinflammation is involved in the maintenance of this neuropathic pain condition. Future studies need to evaluate for differences in epigenetic changes (i.e., methylation, microRNA) between survivors with and without PIPN, which may reflect changes in regulation patterns.
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